Opdualag (nivolumab/ relatlimab-rmbw)

Adult Dosing .

Dosage forms:  INJ

Special Note

[formulation clarification]

Info: nonproprietary name = nivolumab/relatlimab-rmbw

[strength clarification]

combo product contains nivolumab 12 mg and relatlimab 4 mg per mL at fixed 3:1 ratio

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments

melanoma, unresectable or metastatic

[>40 kg]

Dose: 480 mg/160 mg/dose IV q4wk

renal dosing

[see below]

eGFR >30: no adjustment; eGFR <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

mild-moderate impairment: no adjustment; severe impairment: not defined

Peds Dosing .

Dosage forms:  INJ

Special Note

[formulation clarification]

Info: nonproprietary name = nivolumab/relatlimab-rmbw

[strength clarification]

combo product contains nivolumab 12 mg and relatlimab 4 mg per mL at fixed 3:1 ratio

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments

melanoma, unresectable or metastatic

[12 yo and older, >40 kg]

Dose: 480 mg/160 mg/dose IV q4wk

renal dosing

[see below]

eGFR >30: no adjustment; eGFR <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

mild-moderate impairment: no adjustment; severe impairment: not defined